After a review of evidence, the UK Health Security Agency (HSA) said today that it no longer classifies clade 1a and 1b mpox ...

SIGA Technologies (SIGA) announced the appointment of Retired United States Army General John “Jack” Keane to its Board of Directors, effective ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an ...

Our flagship product, TPOXX ® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of ...

Tecovirimat failed to reduce clade II mpox lesions, pain or viral clearance among participants in a study of the antiviral ...

Bethesda, Maryland Saturday, March 15, 2025, 10:00 Hrs [IST] ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical ...

NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions. Colorized transmission electron micrograph of immature mpox virus particles (blue with red viral envelope) ...

83% of participants on tecovirimat achieved clinical resolution, compared to 84% on placebo, which was not significantly different. Pain reduction was similar in both groups, with tecovirimat ...

"The results from STOMP reinforce the value of randomized clinical trials during outbreaks of infectious diseases, like mpox, ...